Combined HT and estrogen-only therapy are associated with a risk for blood clots from deep vein thrombosis. Clinical trials suggest that women with menopausal symptoms who have taken HT are at an increased risk for venous thromboembolism compared with women who have not taken HT. This risk appears greater for oral HT than transdermal treatment. According to the NAMS, for women > 60 years of age or who have started HT > 10 years from the onset of menopause, the risk for coronary heart disease, stroke, venous thromboembolism, and dementia make the benefit-risk ratio for HT less favorable.
Studies have suggested that a history of HT use is associated with a lower rate of colorectal cancer and overall mortality in patients with colorectal cancer. However, there may be a small increased risk for gallbladder disease.
Learn more about menopausal HT.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Richard Scott Lucidi. Fast Five Quiz: Menopause and Hormone Therapy - Medscape - Sep 01, 2022.